Special Issue "Virus-like particle & Nano-particle Vaccines: A Selection of papers from the conference of VLPNPV 2018"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 December 2018) | Viewed by 8964
Interests: virus-like particles; vaccines; infectious diseases; immunology; antibody; allergy; cancer immunotherapy and immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue in Viruses: Virus-Like Particle Vaccines
Special Issue in Vaccines: VLP Based Coronavirus Vaccines
Special Issue in Viruses: Virus-Like Particle Vaccines 2023
This special issue of Vaccines will consist of selected papers from the “Virus-Like Particle & Nano-Particle Vaccines―VLPNPV 2018”, taking place on 25–27 Sptember 2018, in Bern, Switzerland. VLPNPV 2018 is the fifth meeting and will focus on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. This technological innovation has greatly broadened the scope of their use, from immunizing against microbial pathogens to immunotherapy for chronic diseases. Towards this end, virus-like particles have been used to induce auto-antibodies to disease-associated self-molecules involved in chronic diseases, such as hypertension and Alzheimer’s disease. The recognition of the potent immunogenicity and commercial potential for virus-like particles has greatly accelerated research and development activities. During the last decade, three prophylactic virus-like particle vaccines have been registered for human use, while a great many have entered clinical development. The implications of large-scale VLP production will be important for process control, monitorization and optimization. VLP-based and NP-based vaccines updates will be presented with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination. This Special Issue will cover new and novel areas of research pertaining to VLP-based and NP-based vaccines and therefore will represent state-of-the-art and up-to-date coverage of progress.
Prof. Dr. Martin Bachmann
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.